A separate meta-analysis revealed that, compared with patients with T2Dreceiving alternative therapeutic drugs, patients treated with SGLT2 inhibitorshad lower risks of stroke, cardiovascular events, and mortality [40]. Here, SLC5A2 is linked to Stroke.